Immunotherapy: Past, present and future

Nature Medicine

Volumn 9, Issue 3, 2003, Pages 269-277

  Waldmann, Thomas A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; BASILIXIMAB; CANCER VACCINE; CYTOKINE; CYTOTOXIN; DACLIZUMAB; DNA VACCINE; ENDOTOXIN; ETANERCEPT; GAMMA INTERFERON; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN IDIOTYPE; INFLIXIMAB; ISOTOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; OKT 3; PALIVIZUMAB; RADIOISOTOPE; RITUXIMAB; SMALLPOX VACCINE; STREPTAVIDIN; TRASTUZUMAB; TUMOR ANTIGEN; UNINDEXED DRUG; VACCINE; VIRUS ANTIGEN;

ACTIVE IMMUNIZATION; ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; BREAST CANCER; CANCER; CANCER IMMUNIZATION; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CHRONIC DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CPG ISLAND; CROHN DISEASE; DENDRITIC CELL; DNA SEQUENCE; DRUG EFFICACY; GRAFT REJECTION; HISTORY OF MEDICINE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY CELL; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SMALLPOX; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; RADIOISOTOPES; T-LYMPHOCYTES; VACCINES;

VARIOLA VIRUS;

EID: 0037350545     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0303-269     Document Type: Review

References (71)

1. Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P. & Van Pel, A. Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol. 12, 337-365 (1994).
2. Pardoll, D.M. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2, 227-238 (2002).
3. Rosenberg, S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281-287 (1999).
4. Berzofsky, J.A., Ahlers, J.D. & Belyakov, I.M. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1, 209-219 (2001).
5. Boon, T., Coulie, P.G. & Van den Eynde, B. Tumor antigens recognized by T cells. Immunol. Today 18, 267-268 (1997).
6. Srivastava, P.K. Immunotherapy of human cancer: lessons from mice. Nat. Immunol. 1, 363-366 (2000).
7. Köhler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
8. Jones, P.T., Dear, P.H., Foote, J., Newberger, M.S. & Winter, G. Replacing the complementarity determining regions in a human antibody with those from a mouse. Nature 321, 522-525 (1986).
9. Waldmann, T.A. Monoclonal antibodies in diagnosis and therapy. Science 252, 1657-1662 (1991).
10. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1, 118-129 (2001).
11. Gura, T. Magic bullets hit the target. Nature 417, 584-586 (2002).
12. Ehrlich, P. On immunity with special reference to cell life: Croonian lecture. In The Collected Papers of Paul Ehrlich, Vol. II: Immunology and Cancer Research (ed. Himmelweir, B.) 148-192 (Pergammon, London, England, 1956).
13. Coley, W. Further observations upon the treatment of malignant tumors with the toxins of erysipelas and bacillus prodigious with a report of 160 cases. Johns Hopkins Hosp. Bull. 7, 157-162 (1896).
14. Krackhardt, A.M. et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 100, 2123-2131 (2002).
15. Sahin, U. et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92, 11810-11813 (1995).
16. Hunt, D.F. et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255, 1261-1263 (1992).
17. Gilboa, E. The makings of a tumor rejection antigen. Immunity 11, 263-270 (1999).
18. Robbins, P.F. & Kawakami, Y. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8, 626-636 (1996).
19. Lynch, R.G., Graff, R.J., Sirisinha, S., Simms, E.S. & Eisen, H.N. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. USA 69, 1540-1544 (1972).
20. Stevenson, G.T., Elliott, E.V. & Stevenson, F.K. Idiotypic determinants on the surface of immunoglobulin of neoplastic lymphocytes; a therapeutic target. Fed. Proc. 36, 2268-2271 (1977).
21. Miller, R.A., Maloney, D.G., Warnke, R. & Levy, R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Enql. J. Med. 306, 517-522 (1982).
22. Syrengelas, A., Chen, T. & Levy, R. DNA immunization induces protective immunity against B-cell lymphoma. Nat. Med. 2, 1038-1041 (1996).
23. Bendandi, M. et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5, 1171-1177 (1999).
24. Rosenberg, S.A. & White, D.E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for immunotherapy. J. Immunother. 19, 8-14 (1996).
25. Ramshaw, I.A. & Ramsey, A.I. The prime-boost strategy: exciting prospects for improved vaccination. Trends Immunol. Today 21, 163-165 (2000).
26. Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1999).
27. Labeur, M.S. et al. Generation of tumor immunity by bone marrow derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162, 168-175 (1999).
28. Dubois, S., Mariner, J., Waldmann, T.A. & Tagaya, Y. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity 17, 537-547 (2002).
29. Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543 (1993).
30. Shimizu, K., Thomas, E.K., Geidlin, M. & Mule, J.J. Enhancement of tumor lysate and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res. 61, 2618-2624 (2001).
31. Srivastava, P.K. Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2, 185-194 (2002).
32. Parkhurst, M.R. et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified HLA-A 0201 binding residues. J. Immunol. 157, 2539-2548 (1996).
33. Sarobe, P. et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2 binding positions. J. Clin. Invest. 102, 1239-1248 (1998).
34. La Rosa, et al. Enhanced immune activity cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. Blood 97, 1776-1786 (2001).
35. Slansky, J.E. et al. Enhanced antigen-specific anti-tumor immunity with altered peptide ligands that stabilize the MITC-peptide-TCR complex. Immunity 13, 529-538 (2000).
36. Melero, I. et al. Monoclonal antibodies against the 4-IBB T-cell activation molecule eradicate established tumors. Nat. Med. 3, 682-688 (1977).
37. Rosenberg, S.A. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271, 907-913 (1994).
38. Atkins, M.D. et al. High dose recombinant interleukin-2 therapy for patients with metastatic melanoma analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
39. Ahlers, J.D., Dunlop, N., Ailing, D.W., Nara, P.L. & Berzofsky, J.A. Cytokine-inadjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: GM-CSF and TNFα synergize with IL-12 to enhance induction of CTL. J. Immunol. 158, 3947-3958 (1997).
40. Lenardo, M.J. Fas and the art of lymphocyte maintenance. J. Exp. Med. 183, 721-724 (1996).
41. Shevach, E.M. Regulatory T cells in autoimmunity. Ann. Rev. Immunol. 18, 423-449 (2000).
42. Waldmann, T.A. & Tagaya, Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Ann. Rev. Immunol. 17, 19-49 (1999).
43. + T cells in vivo by IL-15. Immunity 8, 591-599 (1998).
44. + memory T cells by opposing cytokines. Science 288, 675-678 (2000).
45. Waldmann, T.A., Dubois, S. & Tagaya, Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14, 105-110 (2001).
46. Chambers, C.A., Kuhns, M.S., Egen, J.G. & Allison, J.P. CTLA-4 mediated inhibition in regulation of T-cell responses: mechanisms and manipulation in tumor immunotherapy. Ann. Rev. Immunol. 19, 565-594 (2001).
47. + T cells: a common basis between tumor immunity and autoimmunity. Immunology 163, 5211-5218 (1999).
48. Onizuka, S. et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59, 3128-3133 (1999).
49. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823-832 (2001).
50. Terabe, M. et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1, 515-520 (2000).
51. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N. Engl. J. Med. 313, 337-342 (1985).
52. Queen, C. et al. A humanized antibody that binds to the interleukin-2 receptor. Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989).
53. Feldmann, M., Brennan, F.M. & Maini, R.N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 14, 397-440 (1996).
54. El-Gabalawy, H.S. & Lipsky, P.E. Why we do not have a cure for rheumatoid arthritis? The scientific basis of rheumatology. Arthritis Res. 4 (suppl. 3), S297-S301 (2002).
55. McLaughlin, P. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833 (1998).
56. Maloney, D.G. et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84, 2457-2466 (1994).
57. Baselga, J., Norton, L., Albanell, J., Kim, Y.-M. & Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825-2831 (1998).
58. Coiffier, B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
59. Slamon, D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
60. Waldmann, T.A. et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82, 1701-1712 (1993).
61. Clynes, R., Tekechi, Y., Moroi, Y., Houghton, A. & Ravetch, J.V. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 95, 652-656 (1998).
62. Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443-446 (2000).
63. Kreitman, R.J. et al. Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 18, 1622-1636 (2000).
64. Kreitman, R.J. et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 94, 3340-3348 (1999).
65. Witzig, T.E. et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab for patients with relapsed or refractory low-grade follicular or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20, 2453-2463 (2002).
66. Waldmann, T.A. et al. Radioimmunotherapy of interleukin-2Rα expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 86, 4063-4075 (1995).
67. 131J Tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96, 1259-1266 (2000).
68. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346, 336-340 (1995).
69. Axworthy, D.B. et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA 97, 1802-1807 (2000).
70. Press, O.W. et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 98, 2535-2543 (2001).
71. Zhang, M. et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213. Blood 100, 208-216 (2002).